Long-term pharmacotherapy for obesity and overweight
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Worldwide prevalence rates of obesity and overweight are rising and safe and effective treatment strategies are urgently needed. A number of anti-obesity agents have been studied in short-term clinical trials, but long-term efficacy and safety need to be established. OBJECTIVES: To assess/compare the effects and safety of approved anti-obesity medications in clinical trials of at least one-year duration. SEARCH STRATEGY: MEDLINE, EMBASE, the Cochrane Controlled Trials Register, the Current Science Meta-register of Controlled Trials, and reference lists of original studies and reviews were searched. Date of last search was December 2002. Drug manufacturers and two obesity experts were contacted in to detect unpublished trials. No language restrictions were imposed. SELECTION CRITERIA: Double-blind, randomised controlled weight loss and weight maintenance trials of approved anti-obesity agents that 1) enrolled adult overweight or obese patients, 2) included a placebo control group or compared two or more anti-obesity drugs 3) used an intention-to-treat analysis, and 4) had a minimum follow-up period of one year. Abstracts and pseudo-randomised trials were not included. DATA COLLECTION AND ANALYSIS: Two reviewers independently assessed all potentially relevant citations for inclusion and methodological quality. The primary outcome measure was weight loss. MAIN RESULTS: Of the eight anti-obesity agents investigated, only orlistat and sibutramine trials met inclusion criteria. Eleven orlistat weight loss studies (four of which reported a second year weight maintenance phase) and five sibutramine studies (three weight loss and two weight maintenance trials) were included. Attrition rates averaged 33% during the weight loss phase of orlistat trials and 43% in sibutramine studies. All patients received lifestyle modification as a co-intervention. Compared to placebo, orlistat-treated patients lost 2.7 kg (95% CI: 2.3 kg to 3.1 kg) or 2.9% (95% CI: 2.3 % to 3.4%) more weight and patients on sibutramine experienced 4.3 kg (95% CI: 3.6 kg to 4.9 kg) or 4.6% (95% CI: 3.8% to 5.4%) greater weight loss. The number of patients achieving ten percent or greater weight loss was 12% (95% CI: 8% to 16%) higher with orlistat and 15% (95% CI: 4% to 27%) higher with sibutramine therapy. Weight loss maintenance results were similar. Orlistat caused gastrointestinal side effects and sibutramine was associated with small increases in blood pressure and pulse rate. REVIEWER'S CONCLUSIONS: Studies evaluating the long-term efficacy of anti-obesity agents are limited to orlistat and sibutramine. Both drugs appear modestly effective in promoting weight loss; however, interpretation is limited by high attrition rates. Longer and more methodologically rigorous studies of anti-obesity drugs that are powered to examine endpoints such as mortality and cardiovascular morbidity are required to fully evaluate any potential benefit of such agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Obesity and the risk of heart failure
Kenchaiah, S., Evans, J. C., Levy, D., Wilson, P. W. F., Benjamin, E. J., Larson, M. G., Kannel, W. B., & Vasan, R. S. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020245 · Cited by 3,093
What is meant by intention to treat analysis? Survey of published randomised controlled trials
Hollis, S., & Campbell, F. (1999) · BMJ · doi:10.1136/bmj.319.7211.670 · Cited by 2,160
Weight gain as a risk factor for clinical diabetes mellitus in women
Colditz, G. A., Willett, W. C., Rotnitzky, A., & Manson, J. E. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-7-199504010-00001 · Cited by 2,064
Impact of Overweight on the Risk of Developing Common Chronic Diseases During a 10-Year Period
Field, A. E., Coakley, E. H., Must, A., Spadano, J. L., Laird, N., Dietz, W. H., Rimm, E., & Colditz, G. A. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.13.1581 · Cited by 1,694
The effect of age on the association between body-mass index and mortality
Stevens, J., Cai, J., Pamuk, E. R., Williamson, D. F., Thun, M. J., & Wood, J. L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801013380101 · Cited by 1,611
Buchanan, T. A., Xiang, A. H., Peters, R. K., Kjos, S. L., Marroquin, A., Goico, J., Ochoa, C., Tan, S., Berkowitz, K., Hodis, H. N., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.9.2796 · Cited by 1,339
Davidson, M. H., Hauptman, J., DiGirolamo, M., Foreyt, J. P., Halsted, C. H., Heber, D., Heimburger, D. C., Lucas, C. P., Robbins, D. C., Chung, J., et al. (1999) · JAMA · doi:10.1001/jama.281.3.235 · Cited by 947
(1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.17.1855 · Cited by 936
Research works printed but not linked: 58
- Apfelbaum, 1999, Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine, American Journal of Medicine, 106, 179, 10.1016/S0002-9343(98)00411-2 · DOI · Paper page
- Bakris, 2002, Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension, Journal of Hypertension, 20, 2257, 10.1097/00004872-200211000-00026 · DOI · Paper page
- Broom, 2002, Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK Multimorbidity Study, International Journal of Clinical Practice, 56, 494, 10.1111/j.1742-1241.2002.tb11307.x · DOI · Paper page
- Davidson, 1999, Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat, Journal of the American Medical Association, 281, 235, 10.1001/jama.281.3.235 · DOI · Paper page
- Finer, 2000, One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor, International Journal of Obesity and Related Metabolic Disorders, 24, 306, 10.1038/sj.ijo.0801128 · DOI · Paper page
- Hauptman, 2000, Orlistat in the long-term treatment of obesity in primary care settings, Archives of Family Medicine, 9, 160, 10.1001/archfami.9.2.160 · DOI · Paper page
- Lindgarde, 2000, The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: The Swedish Multimorbidity Study, Journal of Internal Medicine, 248, 245, 10.1046/j.1365-2796.2000.00720.x · DOI · Paper page
- McMahon, 2000, Efficacy and safety of sibutramine in obese white and african american patients with hypertension, Archives of Internal Medicine, 160, 2185, 10.1001/archinte.160.14.2185 · DOI · Paper page
- McMahon, 2002, Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled by angiotensin converting enzyme inhibitors, Journal of Human Hypertension, 16, 5, 10.1038/sj.jhh.1001298 · DOI
- Rossner, 2000, Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity, Obesity Research, 8, 49, 10.1038/oby.2000.8 · DOI · Paper page
- Sjostrom, 1998, Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients, Lancet, 352, 167, 10.1016/S0140-6736(97)11509-4 · DOI · Paper page
- Sjostrom, 1998, Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients, Lancet, 352, 167, 10.1016/S0140-6736(97)11509-4 · DOI · Paper page
- Smith, 2001, Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity, Journal of Family Practice, 50, 505
- Derosa, 2002, Effects of orlistat, simvastatin, and orlistat plus simvastatin in obese patients with hypercholesterolemia: a randomized, open-label trial, Current Therapeutic Research, Clinical and Experimental, 63, 621, 10.1016/S0011-393X(02)80066-2 · DOI
- Gilbert, 1983, A prospective controlled trial of outpatients treatment for obesity, Human Nutrition. Clinical Nutrition, 37, 21
- Heymsfield, 2000, Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults, Archives of Internal Medicine, 160, 1321, 10.1001/archinte.160.9.1321 · DOI · Paper page
- James, 1997, A one-year trial to assess the value of orlistat in the management of obesity, International Journal of Obesity and Related Metabolic Disorders, 21, S24
- Redmon, 1999, Pharmacologic induction of weight loss to treat type 2 diabetes, Diabetes Care, 22, 896, 10.2337/diacare.22.6.896 · DOI · Paper page
- Wadden, 2001, Benefits of Lifestyle Modification in the Pharmacologic Treatment of Obesity, Archives of Internal Medicine, 161, 218, 10.1001/archinte.161.2.218 · DOI · Paper page
- Weintraub, 1992, Long-term weight control: The national heart, lung, and blood institute funded multimodal intervention study, Clinical Pharmacology and Therapeutics, 51, 581, 10.1038/clpt.1992.68 · DOI · Paper page
- Wirth, 2001, Long-term weight loss with sibutramine, Journal of the American Medical Association, 286, 1331, 10.1001/jama.286.11.1331 · DOI · Paper page
- Zavoral, 1998, Treatment with orlistat reduces cardiovascular risk in obese patients, Journal of Hypertension, 16, 2013, 10.1097/00004872-199816121-00024 · DOI · Paper page
- Andres, 1993, Long-term effects of change in body weight on all-cause mortality, Annals of Internal Medicine, 119, 737, 10.7326/0003-4819-119-7_Part_2-199310011-00022 · DOI · Paper page
- Birmingham, 1999, The cost of obesity in Canada, Canadian Medical Association Journal, 160, 483
- Blackburn, 1995, Effect of degree of weight loss on health benefits, Obesity Research, 3, 2112S
- Bray, 1998, Obesity: a time bomb to be defused, Lancet, 352, 160, 10.1016/S0140-6736(98)22029-0 · DOI
- Calle, 1999, Body-mass index and mortality in a prospective cohort of U.S. adults, New England Journal of Medicine, 341, 1097, 10.1056/NEJM199910073411501 · DOI · Paper page
- Chiasson, 2002, Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial, Lancet, 359, 2072, 10.1016/S0140-6736(02)08905-5 · DOI · Paper page
- Colquitt, 2003, Surgery for morbid obesity, The Cochrane Library
- Egger, 1997, Bias in meta-analysis detected by a simple, graphical test, British Medical Journal, 315, 629, 10.1136/bmj.315.7109.629 · DOI · Paper page
- Flegal, 2002, Prevalence and trends in obesity among US adults, 1999-2000, Journal of the American Medical Association, 288, 1723, 10.1001/jama.288.14.1723 · DOI · Paper page
- Goldstein, 1992, Beneficial effects of modest weight loss, International Journal of Obesity and Related Metabolic Disorders, 16, 397
- Greenway, 1996, Obesity surgery, Endocrinology and Metabolism Clinics of North America, 25, 1005, 10.1016/S0889-8529(05)70367-4 · DOI
- Hu, 2003, Behaviours in relation to risk of obesity and type 2 diabetes melllitus in women, Journal of the American Medical Association, 289, 1785, 10.1001/jama.289.14.1785 · DOI · Paper page
- Jick, 1998, A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation, New England Journal of Medicine, 339, 719, 10.1056/NEJM199809103391102 · DOI · Paper page
- Juni, 2001, Assessing the quality of randomised controlled trials, 87, 10.1002/9780470693926.ch5 · DOI · Paper page
- Khan, 1998, The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs, New England Journal of Medicine, 339, 713, 10.1056/NEJM199809103391101 · DOI · Paper page
- Kissbah, 1994, Regional adiposity and morbidity, Physiological Reviews, 74, 761, 10.1152/physrev.1994.74.4.761 · DOI · Paper page
- Kopelman, 2000, Obesity as a medical problem, Nature, 404, 635, 10.1038/35007508 · DOI · Paper page
- Luque, 1999, Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity, Annals of Pharmacotherapy, 33, 968, 10.1345/aph.18319 · DOI · Paper page
- Manson, 1995, Body weight and mortality among women, New England Journal of Medicine, 333, 677, 10.1056/NEJM199509143331101 · DOI · Paper page
- McNeely, 1998, Orlistat, Drugs, 52, 241, 10.2165/00003495-199856020-00007 · DOI
- Moher, 1999, Improving the quality of reporting of meta-analysis of randomized controlled trials: the QUOROM statement, Lancet, 354, 1896, 10.1016/S0140-6736(99)04149-5 · DOI · Paper page
- NIH, 1993, Methods for voluntary weight loss and control, Annals of Internal Medicine, 119, 764, 10.7326/0003-4819-119-7_Part_2-199310011-00026 · DOI · Paper page
- 1994, Towards prevention of obesity: research directions, Obes Res, 2, 571, 10.1002/j.1550-8528.1994.tb00108.x · DOI
- O'Meara, 2001, A rapid and systematic review of the clinical effectiveness and cost effectiveness of orlistat in the management of obesity, Health Technology Assessment, 5, 10.3310/hta5180 · DOI · Paper page
- O'Meara, 2002, The clinical effectiveness and cost effectiveness of sibutramine in the management of obesity: a technology assessment, Health Technology Assessment, 6, 10.3310/hta6060 · DOI · Paper page
- Ogden, 2002, Prevalence and trends in overweight among US children and adolescents, 1999-2000, Journal of the American Medical Association, 288, 1728, 10.1001/jama.288.14.1728 · DOI · Paper page
- Rimm, 1995, Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men, American Journal of Epidemiology, 141, 1117, 10.1093/oxfordjournals.aje.a117385 · DOI · Paper page
- Schulz, 1995, Empirical evidence of bias: dimensions of methodologic quality associated with estimates of treatment effects in controlled trials, Journal of the American Medical Association, 273, 408, 10.1001/jama.1995.03520290060030 · DOI
- Seidell, 1996, The impact of obesity on health status: some implications for health care costs, International Journal of Obesity and Related Metabolic Disorders, 19(Suppl 6), S13
- Verhagen, 1998, The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus, Journal of Clinical Epidemiology, 51, 1235, 10.1016/S0895-4356(98)00131-0 · DOI · Paper page
- Wadden, 1993, Treatment of obesity by moderate and severe caloric restriction. Results of clinical research trials, Annals of Internal Medicine, 119, 688, 10.7326/0003-4819-119-7_Part_2-199310011-00012 · DOI · Paper page
- Weissman, 1998, An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo, New England Journal of Medicine, 339, 725, 10.1056/NEJM199809103391103 · DOI · Paper page
- Williamson, 1993, The association between weight loss and increased longevity. A review of the evidence, Annals of Internal Medicine, 119, 731, 10.7326/0003-4819-119-7_Part_2-199310011-00021 · DOI · Paper page
- Williamson, 1995, Prospective study of intentional weight loss and mortality in never-smoking overweight US white women aged 40-64 years, American Journal of Epidemiology, 141, 1128, 10.1093/oxfordjournals.aje.a117386 · DOI · Paper page
- Wing, 2000, Type 2 diabetic subjects lose less weight than their overweight spouses, Diabetes Care, 23, 1499
- Wooltorton, 2002, Obesity drug sibutramine (Meridia): hypertension and cardiac arrhythmias, Canadian Medical Association Journal, 166, 1307
Cited by
Manna, P., & Jain, S. K. (2015) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2015.0095 · Cited by 1,145
Changing the future of obesity: science, policy, and action
Gortmaker, S. L., Swinburn, B. A., Levy, D., Carter, R., Mabry, P. L., Finegood, D. T., Huang, T., Marsh, T., & Moodie, M. L. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60815-5 · Cited by 923
Long term pharmacotherapy for obesity and overweight: updated meta-analysis
Rucker, D., Padwal, R., Li, S. K., Curioni, C., & Lau, D. C. W. (2007) · BMJ · doi:10.1136/bmj.39385.413113.25 · Cited by 801
Self-citationChristensen, R., Bartels, E. M., Astrup, A., & Bliddal, H. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.065904 · Cited by 632
Long-term pharmacotherapy for obesity and overweight
Padwal, R. S., Rucker, D., Li, S. K., Curioni, C., & Lau, D. C. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004094.pub2 · Cited by 384
Self-citation
Metadata
- Authors
- Padwal, R., Li, S., & Lau, D.
- Venue
- The Cochrane Database of Systematic Reviews (Protocol)
- Publisher
- John Wiley & Sons, Ltd
- Published
- 2002-07-22
- Issue
- 4
- Pages
- CD004094-CD004094
- OpenAlex
- W2926521198
- Cited by
- 41
- References
- 25
- Type
- reference entry
- Language
- en
- Update notices
- new_version (2003-10-20)
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-term pharmacotherapy for obesity and overweight. https://app.cochat.ai/papers/10.1002/14651858.cd004094
- The paper
- Padwal, R., Li, S., & Lau, D. (2002). Long-term pharmacotherapy for obesity and overweight. The Cochrane Database of Systematic Reviews (Protocol). https://doi.org/10.1002/14651858.cd004094
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.